About NanoSyrinx
NanoSyrinx is a company based in Coventry (United Kingdom) founded in 2018 by Nick R Waterfield and Joe Healey. NanoSyrinx has raised $21.63 million across 5 funding rounds from investors including Lilly, BioCity and BGF. The company has 17 employees as of September 30, 2023. NanoSyrinx offers products and services including Nanosyringe Platform. NanoSyrinx operates in a competitive market with competitors including Sirnaomics, Liquidia, Acorda, Genedit and Ensysce, among others.
- Headquarter Coventry, United Kingdom
- Employees 17 as on 30 Sep, 2023
- Founders Nick R Waterfield, Joe Healey
-
Sectors
TechnologyHealthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nanosyrinx Ltd
- Date of Incorporation 29 Sep, 2018
- Jurisdiction COVENTRY, WEST MIDLANDS, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$21.63 M (USD)
in 5 rounds
-
Latest Funding Round
$13.1 M (USD), Series A
Sep 10, 2024
-
Investors
Lilly
& 9 more
-
Employee Count
17
as on Sep 30, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NanoSyrinx
NanoSyrinx offers a comprehensive portfolio of products and services, including Nanosyringe Platform.
Enables targeted delivery of biologic molecules into cells for therapeutic use.
People of NanoSyrinx
Unlock access to complete
Unlock access to complete
Funding Insights of NanoSyrinx
NanoSyrinx has successfully raised a total of $21.63M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $13.1 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in NanoSyrinx
NanoSyrinx has secured backing from 10 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Lilly, BioCity and BGF.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early & Growth stage tech & offline focused VC firm funding companies in the UK & Ireland
|
Locked | Locked | Locked | |
|
Venture capital investment and support for founders in technology and health sectors.
|
Locked | Locked | Locked | |
|
Deep tech venture capital firm investing in European and global startups.
|
Locked | Locked | Locked |
Investor details for NanoSyrinx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NanoSyrinx
Investment portfolio details for NanoSyrinx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NanoSyrinx
Detailed financials for NanoSyrinx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nanosyrinx Comparisons
Peer comparison for NanoSyrinx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NanoSyrinx
NanoSyrinx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sirnaomics, Liquidia, Acorda, Genedit and Ensysce, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
RNA-based therapeutics for cancer and fibrosis are developed.
|
|
| Locked | Locked | Locked |
Engineered particles & films for life and material sciences applications
|
|
| Locked | Locked | Locked |
Engaged in the development and commercialization of therapies that improve neurological function.
|
|
| Locked | Locked | Locked |
Genetic medicines are delivered using polymer nanoparticle platforms.
|
|
| Locked | Locked | Locked |
Drug delivery solutions via single-walled carbon nanotubes are offered.
|
Detailed competitors of NanoSyrinx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nanosyrinx
Complete news archive for NanoSyrinx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NanoSyrinx
NanoSyrinx was founded in 2018 and raised its 1st funding round 2 years after it was founded.
NanoSyrinx is headquartered in Coventry, United Kingdom.
Joe Healey is the current CEO of NanoSyrinx. They have also founded this company.
NanoSyrinx is a funded company, having raised a total of $21.63M across 5 funding rounds to date.
As of Sep 30, 2023, the latest employee count at NanoSyrinx is 17.
NanoSyrinx was established in 2018 in Coventry, United Kingdom, within the biotechnology sector. A genetically encoded drug delivery device is created using nanosyringes to target cell interiors. The system is designed for production and loading through upstream genetics alone, eliminating further preparation steps. Operations center on advancing intracellular drug administration technologies for potential therapeutic applications.
NanoSyrinx's top competitors include Sirnaomics, Arcturus Therapeutics and Acorda.
NanoSyrinx offers Nanosyringe Platform.
NanoSyrinx has 10 investors. Key investors include Lilly, BioCity, BGF, Octopus Ventures, and IQ Capital.